论文部分内容阅读
环孢菌素(简称CYC)是一种新的免疫抑制剂,能选择性影响T淋巴细胞介导的免疫反应,可广泛用于器官移植。本文采用随机双盲试验评价了本品对顽固性慢性克隆氏病(Crohn’s disease)的疗效。方法 71例克隆氏病患者,研究前停用一切免疫抑制剂至少4周,但研究期间可使用固定剂量的强的松、柳氮磺吡啶或5-氨基水杨酸。随机将病人分为CYC组(37例)和安慰剂组(34例),前组口服CYC的起始日剂量为5～7.5mg/kg,分2次给予;后组给药
Cyclosporine (CYC) is a new immunosuppressive agent that can selectively affect the T lymphocyte-mediated immune response and can be widely used in organ transplantation. This randomized, double-blind trial evaluated the efficacy of this product against refractory chronic Crohn’s disease. Methods 71 patients with Crohn’s disease were randomized to discontinue all immunosuppressive agents for at least 4 weeks prior to the study but a fixed dose of prednisone, sulfasalazine, or 5-aminosalicylic acid was used during the study. Patients were randomly divided into CYC group (37 cases) and placebo group (34 cases), the former group oral CYC starting day dose of 5 ~ 7.5mg / kg, divided into 2 doses; after the group administration